The biologics outsourcing global market is expected to grow at double digit CAGR to reach $70.3 billion by 2025
The biologics outsourcing global market is estimated region wise with various drug discovery, development and manufacturing segments and their market shares. This section also included the market sizing of antibodies, recombinant proteins, vaccines, and others which included gene therapy, cell therapy. The emerging trends and strategies adopted by global biopharmaceutical companies and their impact on outsourcing market were discussed. A list of approved drugs (2012-2016) along with phase wise pipeline analysis for biologics was included.
Although biologics are much costlier than small molecule drugs, these classes of drugs prove to be highly beneficial for the patient and also bring about 40% higher profit to the manufacturers when compared to small molecule drug treatments. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply.
The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery process gets much faster and convenient thus bringing life saving drugs to the market to reach the needy patients.
Key Topics Covered:
1 Biologics Outsourcing Global Market 1.1 Introduction 1.2 Landscape of Biologics Market 1.3 Biologics Global Market 1.4 China Biologics Outsourcing Market 1.5 China Vs India - Biologics Market 1.5.1 Regulations and Government Initiatives 1.5.2 Capabilities and Technologies
2 Market Analysis 2.1 Introduction 2.2 Factors Influencing Market 2.2.1 Drivers and Opportunities 220.127.116.11 Increased Investment in R&D by Pharmaceutical Companies is Increasing the Outsourcing 18.104.22.168 Adoption of Biological Therapies in Disease Management 22.214.171.124 Successful Collaboration and Low Cost for Outsourcing 126.96.36.199 Increasing Biologics Approvals in the Past Year 188.8.131.52 Increasing Chronic and Autoimmune Illnesses 184.108.40.206 Increasing Number of Branded Drugs Going Off-Patent Creates a Scope for Biosimilars 220.127.116.11 Requirement of Novel Biologics Therapeutics for Certain Diseases 18.104.22.168 Increasing Demand for Antibody Conjugates and Bispecific Antibodies 22.214.171.124 Advanced Technologies for Screening, Cell Line Engineering and Bioprocessing 126.96.36.199 Pharma Companies Restricting Their Global Presence, Reducing Manpower, Lack of Facilities for Discovery and Manufacturing of Biologics 2.2.2 Restraints and Threats 188.8.131.52 Intense Complexities in Handling Biologics 184.108.40.206 Requirement of Highly Skilled Technicians 220.127.116.11 High Cost of Drug Development Process 18.104.22.168 Challenges in Oral Formulations With Biologics 22.214.171.124 Stringent Regulatory Frameworks 126.96.36.199 High Capital and Technical Requirements to Obtain Gmp Certifications 188.8.131.52 Limited IP Protection in Developing Regions 184.108.40.206 High Chances of End Stage Failure of Drug 220.127.116.11 Conflict of Interest Between Pharmaceutical Company and Cro
3 Biologics Outsourcing Global Market, Market Analysis 3.1 Introduction 3.2 Discovery and Pre-Clinical Development Process 3.3 Biologics Outsourcing Global Market, by Product Type 3.3.1 Antibody 18.104.22.168 Monoclonal Antibody 22.214.171.124 Bispecific Antibody 126.96.36.199 Antibody Drug Conjugates 188.8.131.52 Others 3.3.2 Recombinant Protein 3.3.3 Vaccines 3.3.4 Others 184.108.40.206 Gene Therapy 220.127.116.11 Cell Therapy 18.104.22.168 Others 3.4 Market Share Analysis 3.5 Company Developments 3.5.1 Agreements, Partnerships & Collaborations 3.5.2 Acquisitions 3.5.3 New Service Launch 3.5.4 Other Developments 3.6 Service Cost Analysis 3.6.1 Antibody Production Service Costs 3.6.2 Custom Monoclonal Antibody Production Service Costs 3.6.3 Custom Polyclonal Antibody Production Service Costs 3.6.4 Protein Production Service Costs 3.6.5 Additional Antibody and Protein Services 3.6.6 Gene Editting Services 3.6.7 Car-T/Nk Platform Services
4 Biologics Outsourcing Global Market - Animal Model Services 4.1 Introduction 4.1.1 Comparison Matrix of Animal Models and Applications 4.1.2 Small Animal Models 4.1.3 Large Animal Models 4.2 Ethics and Regulations 4.3 Alternatives to Animal Models 4.4 Overview of Applications of Animal Models 4.5 Market Share Analysis 4.6 Competitive Landscape 4.7 Company Developments
5 Biologics Outsouring Global Market - Biomanufacturing 5.1 Introduction 5.2 Contract Biomanufacturing, by Process 5.2.1 Biomanufacturing by Mammalian Cell Culture 5.2.2 Biomanufacturing by Microbial Cell Culture 5.2.3 Biomanufacturing by Other Cell Culture 5.3 Contract Biomanufacturing Global Market, by End Users 5.3.1 Contract Biomanufacturing of Diagnostics 5.3.2 Contract Biomanufacturing of Research Reagents 5.3.3 Contract Biomanufacturing of Therapeutics 5.4 Contract Biomanufacturing Global Market, by Region 5.5 Competitive Landscape 5.5.1 Capacity Comparison 5.5.2 Contract Manufacturing Global Market Share, by Leading Players 5.6 Company Developments 5.6.1 Merger and Acquisition by Cmos 5.6.2 Collaborations 5.6.3 Capacity Expansions
6 Biologics Outsourcing Global Market - Cell Line Development 6.1 Introduction 6.1.1 Market Dynamics 6.2 Cell Line Development 6.3 Host Cell Lines 6.4 Cell Line Development Services Market, by Expression System 6.4.1 Microbial Expression Systems 6.4.2 Mammalian Expression System 6.4.3 Others 6.5 Cell Line Development Services, by Cell Type 6.5.1 Cho 6.5.2 Murine/Mouse Myeloma 6.5.3 Baby Hamster Kidney (Bhk) Cells 6.5.4 Hybridoma 6.5.5 Human Embryonic Kidney (Hek) Cells 6.5.6 Human Embryonic Retinal Cells (Per.C6) 6.5.7 Others 6.6 Cell Line Development Services, by Applications 6.6.1 Research 6.6.2 Bioproduction 6.6.3 Diagnostics 6.7 Key Developments 6.8 Market Share Analysis
7 Company Profiles
Abzena Plc Adimab Llc. Albany Molecular Research Inc Beijing Vital Star Biotechnology Co. Ltd. Boehringer Ingelheim Catalent Inc. Charles River Laboratories Crown Biosciences Genoway Genscript Biotech Corporation Gl Biochem Horizon Discovery Group, Plc Jackson Laboratory Innovent Biologics Jhl Biotech Inc. Joinn Laboratories Co. Ltd Lonza Group Merck Kgaa Patheon N.V. Pharmalegacy Biotechnology Pharmaron Prosci Inc. Proteogenix Psychogenics Inc Selexis Sa Shanghai Medicilon Shangpharma Corporation /Shanghai Chempartner Sino Biological Sundia Meditech Co., Ltd. Syngene International Taconic Biosciences Viva Biotech Ltd. Wuxi Apptec